NCI Drug Dictionary

The NCI Drug Dictionary contains technical definitions and synonyms for drugs/agents used to treat patients with cancer or conditions related to cancer. Each drug entry includes links to check for clinical trials listed in NCI's List of Cancer Clinical Trials.

BCMA x CD3 T-cell-engaging antibody CC-93269
A bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; TNFRSF17), and one that is directed against the CD3 antigen found on T lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration of anti-BCMA/CD3 T-cell engaging antibody CC-93269, this bispecific antibody binds to both CD3 on cytotoxic T lymphocytes (CTLs) and BCMA found on BCMA-expressing tumor cells. This activates and redirects CTLs to BCMA-expressing tumor cells, which results in the CTL-mediated death of BCMA-expressing tumor cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival. Check for active clinical trials using this agent. (NCI Thesaurus)

Synonym:anti-BCMA/CD3 bispecific antibody CC-93269
BCMA x CD3 T Cell-engaging antibody CC-93269
BCMA/CD3 T-cell bi-specific antibody CC-93269
BCMA/CD3-directed bispecific T-cell engager antibody CC-93269
BCMAxCD3 BiTE antibody CC-93269
bi-specific antibody CC-93269
Code name:CC 93269